Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 423

1.

GAS6 intron 8 c.834 + 7G > A gene polymorphism in diabetic nephropathy.

Erkoc R, Cikrikcioglu MA, Aintab E, Erek Toprak A, Kilic U, Gok O, Yasin Cetin AI, Zorlu M, Kiskac M, Cakirca M, Erkal SN, Isen HC, Karatoprak C.

Ren Fail. 2015 Apr 14:1-5. [Epub ahead of print]

PMID:
25869052
2.

Stroke subtypes and factors associated with ischemic stroke in Kinshasa, Central Africa.

Tshikwela ML, Londa FB, Tongo SY.

Afr Health Sci. 2015 Mar;15(1):68-73. doi: 10.4314/ahs.v15i1.9.

3.

Poor outcome of experimental ischemic stroke in type 2 diabetic rats: impaired circulating endothelial progenitor cells mobilization.

Yang H, Ma S, Liu Y, Li Y, Wu W, Han E, Jia G, Wang C.

J Stroke Cerebrovasc Dis. 2015 May;24(5):980-7. doi: 10.1016/j.jstrokecerebrovasdis.2014.12.022. Epub 2015 Mar 23.

PMID:
25813059
4.

Omega-3 polyunsaturated fatty acids and non-communicable diseases: meta-analysis based systematic review.

Li D.

Asia Pac J Clin Nutr. 2015;24(1):10-5. doi: 10.6133/apjcn.2015.24.1.21. Review.

5.

Impaired leptomeningeal collateral flow contributes to the poor outcome following experimental stroke in the Type 2 diabetic mice.

Akamatsu Y, Nishijima Y, Lee CC, Yang SY, Shi L, An L, Wang RK, Tominaga T, Liu J.

J Neurosci. 2015 Mar 4;35(9):3851-64. doi: 10.1523/JNEUROSCI.3838-14.2015.

PMID:
25740515
6.

Diabetes Mellitus and Blood-Brain Barrier Dysfunction: An Overview.

Prasad S, Sajja RK, Naik P, Cucullo L.

J Pharmacovigil. 2014 Jun;2(2):125.

7.

[Multiple risk factors models of patients with acute coronary syndromes of different genders].

Sun W, Hu T, Huang X, Zhang Y, Guo J, Wang W, Shi F, Wang P, Wang H, Sun J, Li C.

Zhonghua Yi Xue Za Zhi. 2014 Dec 23;94(47):3735-9. Chinese.

PMID:
25623096
8.

Cardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: a nationwide cohort study.

Chang CH, Chang YC, Lin JW, Chen ST, Chuang LM, Lai MS.

J Clin Endocrinol Metab. 2015 Mar;100(3):1121-9. doi: 10.1210/jc.2014-2443. Epub 2015 Jan 2.

PMID:
25555040
9.

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial.

Udell JA, Bhatt DL, Braunwald E, Cavender MA, Mosenzon O, Steg PG, Davidson JA, Nicolau JC, Corbalan R, Hirshberg B, Frederich R, Im K, Umez-Eronini AA, He P, McGuire DK, Leiter LA, Raz I, Scirica BM; SAVOR-TIMI 53 Steering Committee and Investigators.

Diabetes Care. 2015 Apr;38(4):696-705. doi: 10.2337/dc14-1850. Epub 2014 Dec 31.

PMID:
25552421
10.

Health outcomes of vitamin D. Part II. Role in prevention of diseases.

Wranicz J, Szostak-Węgierek D.

Rocz Panstw Zakl Hig. 2014;65(4):273-9.

11.

Persistent cerebrovascular damage after stroke in type two diabetic rats measured by magnetic resonance imaging.

Ding G, Yan T, Chen J, Chopp M, Li L, Li Q, Cui C, Ning R, Jiang Q.

Stroke. 2015 Feb;46(2):507-12. doi: 10.1161/STROKEAHA.114.007538. Epub 2014 Dec 18. Erratum in: Stroke. 2015 Feb;46(2):e53.

PMID:
25523056
12.

Type 2 diabetes is associated with a worse functional outcome of ischemic stroke.

Tziomalos K, Spanou M, Bouziana SD, Papadopoulou M, Giampatzis V, Kostaki S, Dourliou V, Tsopozidi M, Savopoulos C, Hatzitolios AI.

World J Diabetes. 2014 Dec 15;5(6):939-44. doi: 10.4239/wjd.v5.i6.939.

13.

Body mass index and stroke risk among patients with type 2 diabetes mellitus.

Li W, Katzmarzyk PT, Horswell R, Zhang Y, Zhao W, Wang Y, Johnson J, Hu G.

Stroke. 2015 Jan;46(1):164-9. doi: 10.1161/STROKEAHA.114.006718. Epub 2014 Dec 2.

PMID:
25468880
14.

Risk of cardiovascular disease: the effects of diabetes and anti-diabetic drugs - a nested case-control study.

Gejl M, Starup-Linde J, Scheel-Thomsen J, Gregersen S, Vestergaard P.

Int J Cardiol. 2015 Jan 15;178:292-6. doi: 10.1016/j.ijcard.2014.11.096. Epub 2014 Nov 12.

PMID:
25465309
15.

Health care costs attributable to overweight calculated in a standardized way for three European countries.

Lette M, Bemelmans WJ, Breda J, Slobbe LC, Dias J, Boshuizen HC.

Eur J Health Econ. 2014 Nov 29. [Epub ahead of print]

PMID:
25432787
16.

Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study.

Kim SC, Glynn RJ, Liu J, Everett BM, Goldfine AB.

Acta Diabetol. 2014 Dec;51(6):1015-23. doi: 10.1007/s00592-014-0663-2. Epub 2014 Oct 14.

PMID:
25311055
17.
18.

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.

Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL; SAVOR-TIMI 53 Steering Committee and Investigators*.

Circulation. 2014 Oct 28;130(18):1579-88. doi: 10.1161/CIRCULATIONAHA.114.010389. Epub 2014 Sep 4.

PMID:
25189213
19.

Exendin-4 reduces ischemic brain injury in normal and aged type 2 diabetic mice and promotes microglial M2 polarization.

Darsalia V, Hua S, Larsson M, Mallard C, Nathanson D, Nyström T, Sjöholm Å, Johansson ME, Patrone C.

PLoS One. 2014 Aug 7;9(8):e103114. doi: 10.1371/journal.pone.0103114. eCollection 2014.

20.

Acute heart transplant graft failure in association with hyperosmolar hyperglycemia state.

Sadat K, Morsy M, Khalife WI.

J Card Surg. 2014 Sep;29(5):737-9. doi: 10.1111/jocs.12408. Epub 2014 Jul 19.

PMID:
25041938
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk